

Mapi Pharma

Value-Added High Barrier-
to-Entry Pharmaceuticals

In three years from now...



- Mapi Pharma is an emerging fully integrated pharmaceutical company focused on Super 505(b)(2) products, API and generic drugs
- Lead product is GA Depot, the lifecycle management version of Copaxone[®] (glatiramer acetate), currently the leading product for treating MS, with sales of \$4.3 billion in 2016
- Mapi has have full control over the supply chain with in-house plants of API and drug products

Highlights

- **Lead Product:** Glatiramer Acetate (GA) Depot - once monthly Lifecycle Management (LCM) version of Copaxone®
 - Phase II trial completed
 - Pivotal Phase III trial initiating in 2017 with interim data in 2018
 - Patent protection for depot long-acting formulation in the U.S. until 2030, extension potential to 2037
 - PPMS Phase II, approved by MOH and Helsinki committees in Israel
- **Pipeline of multiple late-stage products:** including extended release forms of commercially successful products as well as high barrier-to-entry generics
- **Multiple APIs and Formulations** expected to launch in the next 36 months
- **Experienced team** with track record of developing and commercializing products that contributed to Copaxone®'s global success




GA Depot

GA Depot

Mapi is developing GA Depot as a premium drug to Copaxone® for MS patients with improved compliance, convenience and clinical outcome

- Completed Phase II, development under 505(b)(2), single pivotal Phase III layout approved by FDA
- GA Depot 40mg IM, once every 4 weeks
- Maximize compliance to >90%, injection by nurse at patient's home
- ~10 micron GA-loaded PLGA microspheres
- Linear release profile over 30-day period
- Intended to improve: QoL, safety by fewer AEs and tolerability
- Good efficacy suggested in Phase II results
- Patients and neurologists prefer a once-monthly injection
- Mapi was granted US patents titled depot systems comprising GA, administered from 1 week to 6 months, expires Aug. 2030; three new patent applications under process to extend to 2037
- **Extended indication:** PPMS in Phase II





API Plant

API Plant – Neot Hovav

- **Location:** Israel's designated industrial chemical park, Neot Hovav
- **Size:** 3 acres, designed as a multipurpose versatile facility ready to support first 5-6 years of business plan
- **Status:** Qualified and operating
- “Preferred Enterprise” granted governmental cash grants of 20% (may increase by 4%)
- Entitled to a reduced tax rate of 7.5% (compared to a 24% corporate income tax rate)
- Manufacturing GA API